Merck & Co., Inc: Chickenpox trials

The registry lists 28 Chickenpox studies with Merck & Co., Inc as lead sponsor. 0 are open to participants now and 19 have results posted.

Phase 2 2Phase 3 21Phase 4 2No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058)CompletedNCT03843632Phase 3Results posted
• Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)CompletedNCT03239873Phase 3Results posted
• Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)CompletedNCT02062502Phase 3Results posted
• Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)CompletedNCT01536405Phase 3Results posted
• A Study to Evaluate Long-term Impact of VARIVAX Among Children and Adolescents (V210-036)(COMPLETED)CompletedNCT01077804Results posted
• Re-examination Study For Varivax (V210-059 AM2)CompletedNCT01062061Results posted
• ProQuad Dose Selection Study (V221-011)(COMPLETED)CompletedNCT00986232Phase 2Results posted
• A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)CompletedNCT00985166Phase 3Results posted
• Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)CompletedNCT00985153Phase 3Results posted
• Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric VaccinesCompletedNCT00984295Phase 3Results posted
• ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED)CompletedNCT00975507Phase 3Results posted
• A Study of ProQuad™ in Healthy Children in Korea (V221-023)TerminatedNCT00839917Phase 3Results posted
• Study to Test the Safety and Immunogenicity of VARIVAX (2007 Process) (Study V210-057) (Completed)CompletedNCT00822237Phase 3Results posted
• Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)CompletedNCT00566527Phase 3Results posted
• Safety Study of ProQuad® rHA in Infants (V221-037)CompletedNCT00560755Phase 3Results posted
• Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)CompletedNCT00432042Phase 3Results posted
• ProQuad® Intramuscular vs SubcutaneousCompletedNCT00402831Phase 3Results posted
• Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)CompletedNCT00326183Phase 4Results posted
• V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)CompletedNCT00109343Phase 3Results posted
• A Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Manufactured With a New Process (V210-062)WithdrawnNCT01626794Phase 3
• ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)CompletedNCT01600079
• Safety,Tolerability and Immunogenicity of Vaccination With VARIVAX in Healthy Indian Children (V210-056)CompletedNCT00496327Phase 3
• ZOSTAVAX(R) Local Registration Trial (V211-019)CompletedNCT00444860Phase 3
• Safety Study of a Refrigerator-stable Formulation of VARIVAX®CompletedNCT00432731Phase 4
• Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011)CompletedNCT00432523Phase 3
• Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)CompletedNCT00092430Phase 3
• Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED)CompletedNCT00092404Phase 2
• A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)CompletedNCT00092391Phase 3